Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

New England Journal of Medicine

Volumn 380, Issue 24, 2019, Pages 2295-2306

  Perkovic, V ^a,b   Jardine, M J ^a,c   Neal, B ^a,d,f   Bompoint, S ^a   Heerspink, H J L ^h   Charytan, D M ^i,j   Edwards, R ^m   Agarwal, R ⁿ   Bakris, G ^o   Bull, S ^m   Cannon, C P ^j,k   Capuano, G ^m   Chu, P L ^m   De Zeeuw, D ^h   Greene, T ^p   Levin, A ^q   Pollock, C ^e   Wheeler, D C ^g   Yavin, Y ^m   Zhang, H ^s   Zinman, B ^r   Meininger, G ^m   Brenner, B M ^j,k,l   Mahaffey, K W ^t   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

^l HARVARD MEDICAL SCHOOL   (United States)

^m JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁿ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^p UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^r MOUNT SINAI HOSPITAL   (Canada)

^s PEKING UNIVERSITY FIRST HOSPITAL   (China)

^t STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CREATININE; PLACEBO;

ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADULT; ALBUMINURIA; AMPUTATION; ARTICLE; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIABETIC KETOACIDOSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FRACTURE; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL CELL CARCINOMA; TREATMENT OUTCOME; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DIABETIC NEPHROPATHY; FOLLOW UP; GLOMERULUS FILTRATION RATE; MORTALITY;

AGED; CANAGLIFLOZIN; CARDIOVASCULAR DISEASES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85066483412     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1811744     Document Type: Article

References (21)

1. International Diabetes Federation. IDF diabetes atlas. 8th ed. Brussels: International Diabetes Federation, 2017.
2. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 2015;385:1975-82.
3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-57.
6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
7. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380: 347-57.
8. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol 2018;6:691-704.
9. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-34.
10. Jardine MJ, Mahaffey KW, Neal B, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017;46:462-72.
11. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97.
12. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990;70:665-99.
13. Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM. Elevated plasma atrial natriuretic peptide levels in diabetic rats: potential mediator of hyperfil-tration. J Clin Invest 1987;80:670-4.
14. Sternlicht H, Bakris GL. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2i): more than osmotic diuresis. Curr Hypertens Rep 2019; 21(2):12.
15. Esterline RL, Vaag A, Oscarsson J, Vora J. Mechanisms in endocrinology — SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism? Eur J Endocrinol 2018;178(4):R113-R125.
16. Chakraborty S, Galla S, Cheng X, et al. Salt-responsive metabolite, β-hydroxybuty-rate, attenuates hypertension. Cell Rep 2018;25(3):677-689.e4.
17. Schutten JC, Joosten MM, de Borst MH, Bakker SJL. Magnesium and blood pressure: a physiology-based approach. Adv Chronic Kidney Dis 2018;25:244-50.
18. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS Program. Circulation 2018;138:458-68.
19. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 2016;37:1526-34.
20. Inzucchi SE, Iliev H, Pfarr E, Zinman B. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 2018;41(1): e4-e5.
21. Guyatt GH, Briel M, Glasziou P, Bassler D, Montori VM. Problems of stopping trials early. BMJ 2012;344:e3863.